Pharma Giant Abandons Superbug Drug Amid Antibiotic Market Collapse

A major pharmaceutical company's decision to discontinue a critical superbug drug has exposed a catastrophic flaw in healthcare economics. Merck, the American multinational pharmaceutical giant, has officially withdrawn Recarbrio from the U.S. market, seven years after it received FDA approval.

The withdrawal of Recarbrio highlights the paradoxical nature of the antibiotic market model. Drugs designed to cure the world's most dangerous superbugs are intentionally restricted in their use, preventing them from generating enough revenue to sustain operations.

This is not a medical failure but rather a structural economic one. Pharmaceutical companies spend billions developing these compounds only for hospitals to lock them away and avoid using them as much as possible.